See more : Charlie’s Holdings, Inc. (CHUC) Income Statement Analysis – Financial Results
Complete financial analysis of PolyPid Ltd. (PYPD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PolyPid Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Thrace Plastics Holding Company S.A. (PLAT.AT) Income Statement Analysis – Financial Results
- Caregen Co., Ltd. (214370.KQ) Income Statement Analysis – Financial Results
- AUN CONSULTING, Inc. (2459.T) Income Statement Analysis – Financial Results
- BINEX Co., Ltd. (053030.KQ) Income Statement Analysis – Financial Results
- PT Waskita Karya (Persero) Tbk (WSKT.JK) Income Statement Analysis – Financial Results
PolyPid Ltd. (PYPD)
About PolyPid Ltd.
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.82M | 1.72M | 1.12M | 1.01M | 947.00K | 411.00K | 205.00K | 127.00K | 108.00K | 0.00 | 0.00 |
| Gross Profit | -1.82M | -1.72M | -1.12M | -1.01M | -947.00K | -411.00K | -205.00K | -127.00K | -108.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 16.15M | 27.99M | 30.42M | 16.95M | 14.08M | 12.55M | 9.74M | 7.71M | 5.63M | 2.64M | 1.38M |
| General & Administrative | 0.00 | 8.01M | 9.48M | 7.70M | 4.48M | 5.27M | 4.06M | 2.55M | 2.93M | 938.00K | 410.00K |
| Selling & Marketing | 0.00 | 2.89M | 2.97M | 1.61M | 887.00K | 549.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.90M | 10.90M | 12.45M | 9.32M | 4.48M | 5.81M | 4.06M | 2.55M | 2.93M | 938.00K | 410.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 21.05M | 38.89M | 42.88M | 26.27M | 18.56M | 18.36M | 13.80M | 10.26M | 8.57M | 3.58M | 1.79M |
| Cost & Expenses | 22.87M | 38.89M | 42.88M | 26.27M | 18.56M | 18.36M | 13.80M | 10.26M | 8.57M | 3.58M | 1.79M |
| Interest Income | 548.00K | 267.00K | 468.00K | 474.00K | 60.00K | 126.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.71M | 1.02M | 0.00 | 17.00K | 15.00K | 42.00K | 40.69M | 1.13M | -1.53M | 0.00 | 0.00 |
| Depreciation & Amortization | 1.82M | 1.72M | 1.12M | 1.01M | 947.00K | 411.00K | 205.00K | 127.00K | 108.00K | 71.00K | 60.00K |
| EBITDA | -20.26M | -36.37M | -41.48M | -35.86M | -5.94M | -42.15M | -13.60M | -10.13M | -7.95M | -3.51M | -1.73M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -22.87M | -38.89M | -42.88M | -26.27M | -18.56M | -18.36M | -13.80M | -10.26M | -11.28M | -3.58M | -1.79M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -929.00K | -540.00K | 544.00K | -10.60M | 11.66M | 24.28M | -40.69M | -1.13M | -1.18M | -305.00K | -3.00K |
| Income Before Tax | -23.80M | -39.43M | -42.33M | -36.87M | -6.91M | 5.92M | -54.49M | -11.39M | -9.75M | -3.88M | -1.79M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 69.00K | 97.00K | -1.62M | -1.55M | -11.66M | -24.28M | 40.69M | 1.13M | -1.53M | 305.00K | 3.00K |
| Net Income | -23.87M | -39.53M | -40.71M | -35.32M | 4.75M | 5.92M | -54.49M | -11.39M | -8.22M | -3.88M | -1.79M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -16.99 | -61.04 | -65.24 | -110.59 | 10.72 | 13.35 | -185.29 | -38.74 | -18.81 | -19.79 | -4.04 |
| EPS Diluted | -16.99 | -61.04 | -65.24 | -110.59 | 10.72 | 13.35 | -185.29 | -38.74 | -18.81 | -19.79 | -4.04 |
| Weighted Avg Shares Out | 1.40M | 647.56K | 624.05K | 319.41K | 443.22K | 443.22K | 294.07K | 294.07K | 437.07K | 196.22K | 443.22K |
| Weighted Avg Shares Out (Dil) | 1.40M | 647.56K | 624.05K | 319.41K | 443.22K | 443.22K | 294.07K | 294.07K | 437.07K | 196.22K | 443.22K |
PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company's Ongoing D-PLEX₁₀₀ Phase 3 Trial
PETACH TIKVA, Israel, June 10, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a virtual Key Opinion Leader (KOL) event on...
PolyPid Ltd (PYPD) Q1 2024 Earnings Call Transcript
PolyPid Ltd (NASDAQ:PYPD ) Q1 2024 Earnings Conference Call May 8, 2024 8:30 AM ET Company Participants Brian Ritchie - IR Dikla Czaczkes Akselbrad - CEO & Director Jonny Missulawin - Chief Financial Officer Ori Warshavsky - Chief Operating Officer,...
PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results
More Than 200 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX 100 for the Prevention of Abdominal Colorectal Surgical Site Infections
PolyPid to Participate in Citizens JMP Life Sciences Conference
PETACH TIKVA, Israel, May 01, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that company management will present at the Citizens JMP Life Sciences Conference taking...
PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections
Study Approximately Half Enrolled to the Planned Unblinded Interim Analysis Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up Top-line Results Expected in Second Half of 2024 PETACH TIKVA, Israel, April 30, 2024 (GLOBE NEWSWIRE)...
PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024
PETACH TIKVA, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2024 financial results and operational highlights before...
PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference
PETACH TIKVA, Israel, Feb. 28, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Company management will participate in a fireside chat at the Barclays 26th Annual...
PolyPid Ltd. (PYPD) Upgraded to Buy: What Does It Mean for the Stock?
PolyPid Ltd. (PYPD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PolyPid Ltd (PYPD) Q4 2023 Earnings Call Transcript
PolyPid Ltd (PYPD) Q4 2023 Earnings Call Transcript
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
More Than 100 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX 100 for the Prevention of Abdominal Colorectal Surgical Site Infections
Source: https://incomestatements.info
Category: Stock Reports